Discovery of a Novel Glucagon-like Peptide-1 (GLP-1) Analogue from Bullfrog and Investigation of Its Potential for Designing GLP-1-Based Multiagonists
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Neng Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, PR China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Guangxi Medical University, Natural Science Foundation of Guangxi Zhuang Autonomous Region, Science Fund for Distinguished Young Scholars of Guangxi Province.
Abstract (Originalsprache)
In this study, we aimed to discover novel GLP-1 analogues from natural sources. We investigated GLP-1 analogues from fish and amphibians, and bullfrog GLP-1 (bGLP-1) showed the highest potency. Starting with bGLP-1, we explored the structure-activity relationship and performed optimization and long-acting modifications, resulting in a potent analogue called 2f. Notably, 2f exhibited superior effects on food intake, glycemic control, and body weight compared to semaglutide. Furthermore, we explored the usefulness of bGLP-1 in designing GLP-1-based multiagonists. Using the bGLP-1 sequence, we designed novel dual GLP-1/glucagon receptor agonists and triple GLP-1/GIP/glucagon receptor agonists. The selected dual GLP-1/glucagon receptor agonist 3o and triple GLP-1/GIP/glucagon receptor agonist 4b exhibited significant therapeutic effects on lipid regulation, glycemic control, and body weight. Overall, our study highlights the potential of discovering potent GLP-1 receptor agonists from natural sources. Additionally, utilizing natural GLP-1 analogues for designing multiagonists presents a practical approach for developing antiobesity and antidiabetic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, PR China.
- School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China.
- Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi 530021, PR China.
- School of Pharmacy, Youjiang Medical University for Nationalities, 98 Chengxiang Road, Baise, Guangxi 533000, PR China.
ORCID-Profile: Jing Han
Förderung
- Guangxi Medical University
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- Science Fund for Distinguished Young Scholars of Guangxi Province
- Postdoctoral Science Foundation of Guangxi Province of China
- National Natural Science Foundation of China
- Special Funds for Science and Technology Development under the Guidance of the Central Government
Zitieren
APA
Jiang, N., Su, D., Chen, Huang, S., Tang, C., Jing, L., Yang, C., Zhou, Z., Yan, Z., & Han, J. (2024). Discovery of a Novel Glucagon-like Peptide-1 (GLP-1) Analogue from Bullfrog and Investigation of Its Potential for Designing GLP-1-Based Multiagonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01049
Vancouver
Jiang N, Su D, Chen, Huang S, Tang C, Jing L, et al. Discovery of a Novel Glucagon-like Peptide-1 (GLP-1) Analogue from Bullfrog and Investigation of Its Potential for Designing GLP-1-Based Multiagonists. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01049
BibTeX
@article{Jiang2024,
author = {Jiang, Neng and Su, Di and Chen, De and Huang, Shutong and Tang, Chunli and Jing, Lin and Yang, Caiyan and Zhou, Zhongbo and Yan, Zhiming and Han, Jing},
title = {Discovery of a Novel Glucagon-like Peptide-1 (GLP-1) Analogue from Bullfrog and Investigation of Its Potential for Designing GLP-1-Based Multiagonists},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01049}
}
EUVIMED